Alterity Therapeutics (NASDAQ:ATHE) Coverage Initiated by Analysts at Canaccord Genuity Group

Canaccord Genuity Group assumed coverage on shares of Alterity Therapeutics (NASDAQ:ATHE) in a research report report published on Wednesday,Benzinga reports. The brokerage issued a speculative buy rating on the stock.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Alterity Therapeutics in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $12.00.

Alterity Therapeutics Price Performance

Shares of ATHE opened at $2.92 on Wednesday. The company’s 50-day simple moving average is $3.90 and its 200-day simple moving average is $4.41. Alterity Therapeutics has a 1 year low of $2.04 and a 1 year high of $7.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ATHE. Greenleaf Trust purchased a new stake in shares of Alterity Therapeutics in the 2nd quarter valued at approximately $70,000. Citadel Advisors LLC purchased a new position in Alterity Therapeutics in the third quarter valued at $83,000. HB Wealth Management LLC acquired a new stake in Alterity Therapeutics in the third quarter valued at $220,000. Finally, Twin Lakes Capital Management LLC raised its stake in Alterity Therapeutics by 2,250.3% in the third quarter. Twin Lakes Capital Management LLC now owns 139,258 shares of the company’s stock valued at $524,000 after buying an additional 133,333 shares in the last quarter. Institutional investors and hedge funds own 2.14% of the company’s stock.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.